This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
This is a web analytics service.
Processing company
  • Google Ireland Limited
  • Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
  • Facebook Ireland Limited
  • 4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
  • advertising
  • Marketing
  • Retargeting
  • Analyse
  • Tracking
Technologies Used
  • Cookies
Data Attributes
  • Pixel specific data
  • Http-Header
  • Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • Facebook user ID
  • Browser information
  • Usage data
  • Geräteinformationen
  • Non-sensitive custom data
  • Referrer URL
  • Pixel ID
  • Location information
  • Pixel specific data
  • User behaviour
  • Ads viewed
  • Interactions with advertisement, services, and products
  • Marketing information
  • Content viewed
  • IP address
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Facebook Inc.
This is a web analytics service.
Processing company
  • Zoom Analytics Ltd.
  • Petah Tikva, Israel
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
Hemofarm Marked 10 Years of Successful Business in Bosnia and Herzegovina
22. February 2013.
Hemofarm d.o.o. Banja Luka, a pharmaceutical factory in Bosnia and Herzegovina, marked an important anniversary – a decade of successful business.

Together with the host, Director of Hemofarm d.o.o. Banja Luka, Mr Aleksandar Veselinović, Managing Director of Hemofarm, Mr Ronald Seeliger and the company management, the celebration of ten years of manufacturing of medicines in Banja Luka was also attended by President of Republika Srpska, Mr Milorad Dodik, as well as numerous representatives of state institutions and partner companies.

Hemofarm has been present on the BH market since 1996. A contract on joint investment between Hemofarm from Vršac and Čajavec Holding from Banja Luka was signed then. The contract was a starting point for construction of the solid dosage forms factory, which was put into operation on February 21st, 2003.

Successful manufacturer and exporter of medicines, Hemofarm d.o.o. Banja Luka is one of the bearers of pharmaceutical industry, as well as the entire economy of Bosnia and Herzegovina today.
Among other during his speech, President Dodik said “that one needed not only political, but also entrepreneurial courage to come and start business in Republika Srpska ten years ago, and Hemofarm leaders did have the sagacity to do so. If it weren’t for this,” Dodik pointed out, “not even the subsequent investments, which we now see as very successful, could probably not have been accomplished.”

“This is why this beginning was so important for the overall success of Hemofarm. The key moment was also privatisation and the fact that Hemofarm bound its business success for the team of people who worked on the accomplishment of this business success”, said Dodik.

President of Republika Srpska thanked everyone who contributed to the success of Hemofarm, insisting that this is a brand everyone could be proud of nowadays. Dodik added that the management of Hemofarm has an optimistic approach regarding Hemofarm Banja Luka.

Addressing the distinguished guests, Managing Director of Hemofarm, Mr Ronald Seeliger, among other, said the following:“It is our goal that Hemofarm be the leader in the region, and the domestic market is of strategic value for us and STADA Group has important and serious plans here. Hemofarm d.o.o. Banja Luka is a very prospective production site of great importance not only to Hemofarm, but to the entire STADA Group. In addition to the transfer of a growing number of products to this factory in Banja Luka, STADA Group has, in the course of the past 5 years alone, invested a lot into this factory, with the intention of improving the infrastructure, and expanding the portfolio with affordable, efficient and high-quality medicines of the latest generation. Care, quality, affordability and trust are our key values on which we base the strategy of business operations of Hemofarm. As a socially responsible company, we are going to continue improving our activities dedicated to the community we live and work in, dedicated to all of you for all the best“.

Director of Hemofarm d.o.o. Banja Luka, Mr Aleksandar Veselinović, said that this company has tripled its production over the last five years. He indicated that Hemofarm d.o.o. Banja Luka is among the leaders, from the financial point of view, while it holds the first place in the number of sold packs of medicines in BH.

Mr Veselinović stressed that Hemofarm d.o.o. Banja Luka exports 94 % of the products, 48 % of which to the EU, and 46 % of which to the countries of Western Balkans.

“This would not have been possible if this factory for manufacturing of medicines had not been conceived upon highest standards, supreme technological equipment, professional personnel and their commitment”, said Veselinović.

On 10,000 square meters of the production complex in Banja Luka, Hemofarm annually manufactures around 570 million tablets, i.e. more than 17 million packs.

Since August 2006, Hemofarm has been a part of German STADA Group, one of the largest generic pharmaceutical companies in Germany. With high quality and yet affordable pharmaceutical products, Hemofarm is present in 30 countries on three continents. Hemofarm manufactures medical products in 11 out of a total of 14 pharmacotherapeutic groups.